Literature DB >> 28295528

Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement.

Chuyen Thi Hong Nguyen1, Naotomo Kambe1, Izumi Kishimoto1, Ikuko Ueda-Hayakawa1, Hiroyuki Okamoto1.   

Abstract

Skin lesions in sarcoidosis are often the initial symptoms that enable the dermatologist to be the first to diagnose this granulomatosis. However, diagnosis is sometimes very problematic. In 2015, the diagnostic criteria for sarcoidosis were updated in Japan, with elevated serum soluble interleukin-2 receptor (sIL-2R) replacing negative tuberculin reaction. Therefore, we assessed the clinical utility of sIL-2R compared with two other common markers, angiotensin-converting enzyme (ACE) and lysozyme, in patients who visited the dermatology clinic. Data from 72 patients showed that sIL-2R was more sensitive than both ACE and lysozyme in supporting a diagnosis of sarcoidosis (52.8%) compared with ACE (29%) and lysozyme (26.4%). Additionally, the sIL-2R level was significantly higher in patients with multiple organ involvement and parenchymal infiltration. Patients with elevated sIL-2R levels had higher serum ACE and lysozyme levels, a higher incidence of pulmonary involvement, more severe chest radiographic stage and a high incidence of expression-specific signs by imaging analysis. Receiver-operator curve analysis showed that sIL-2R was a better marker at the threshold cut-off point compared with ACE and lysozyme for identifying patients with multiple organ involvement, detecting patients with pulmonary disease and parenchymal infiltration as well as predicting the presence of specific signs in the diagnosis of sarcoidosis. Moreover, the kinetics of sIL-2R levels correlated closely with clinical manifestations, in contrast to the modest changes of ACE and lysozyme levels during the follow-up period. In conclusion, sIL-2R may be considered a good marker for diagnosis and a potential indicator of disease activity.
© 2017 Japanese Dermatological Association.

Entities:  

Keywords:  angiotensin-converting enzyme; granuloma; interleukin-2 receptor; lymphocyte activation; sarcoidosis

Mesh:

Substances:

Year:  2017        PMID: 28295528     DOI: 10.1111/1346-8138.13792

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  14 in total

Review 1.  [Sarcoidosis : Dermatological view of a rare multisystem disease].

Authors:  T Giner; S Benoit; H Kneitz; M Goebeler
Journal:  Hautarzt       Date:  2017-07       Impact factor: 0.751

2.  Role of Neuron-Specific Enolase in the Diagnosis and Disease Monitoring of Sarcoidosis.

Authors:  Noriaki Sunaga; Yasuhiko Koga; Yoshimasa Hachisu; Koichi Yamaguchi; Masaki Aikawa; Norimitsu Kasahara; Yosuke Miura; Hiroaki Tsurumaki; Masakiyo Yatomi; Reiko Sakurai; Toshitaka Maeno; Takeshi Hisada
Journal:  Can Respir J       Date:  2022-05-26       Impact factor: 2.130

3.  Serum soluble interleukin-2 receptor level is a predictive marker for EBUS-TBNA-based diagnosis of sarcoidosis.

Authors:  Jun Miyata; Takunori Ogawa; Yoichi Tagami; Takashi Sato; Mikie Nagayama; Toshiyuki Hirano; Naofumi Kameyama; Koichi Fukunaga; Akihiko Kawana; Takashi Inoue
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-15       Impact factor: 0.670

4.  Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease.

Authors:  A F Karim; L E M Eurelings; R D Bansie; P M van Hagen; J A M van Laar; W A Dik
Journal:  Mediators Inflamm       Date:  2018-03-01       Impact factor: 4.711

5.  YKL-40, Soluble IL-2 Receptor, Angiotensin Converting Enzyme and C-Reactive Protein: Comparison of Markers of Sarcoidosis Activity.

Authors:  Pelin Uysal; Sinem Durmus; Volkan Sozer; Remise Gelisgen; Ekrem Cengiz Seyhan; Fusun Erdenen; Gonul Simsek; Hafize Uzun
Journal:  Biomolecules       Date:  2018-08-28

6.  A young man with numbness in arms and legs: From the National Multiple Sclerosis Society Case Conference Proceedings.

Authors:  Andrew R Romeo; Robert P Lisak; Ethan Meltzer; Edward J Fox; Esther Melamed; Ashlea Lucas; Leorah Freeman; Teresa C Frohman; Kathleen Costello; Scott S Zamvil; Elliot M Frohman; Jeffrey M Gelfand
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-10-23

Review 7.  Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects.

Authors:  Raisa Kraaijvanger; Montse Janssen Bonás; Adriane D M Vorselaars; Marcel Veltkamp
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

Review 8.  Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments.

Authors:  Rashi Jain; Dhananjay Yadav; Nidhi Puranik; Randeep Guleria; Jun-O Jin
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

9.  Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis.

Authors:  Laura E M Eurelings; Jelle R Miedema; Virgil A S H Dalm; Paul L A van Daele; P Martin van Hagen; Jan A M van Laar; Willem A Dik
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

10.  Ocular sarcoidosis: clinical experience and recent pathogenetic and therapeutic advancements.

Authors:  Rosanna Dammacco; Jyotirmay Biswas; Tero T Kivelä; Francesco Alfredo Zito; Patrizia Leone; Alberto Mavilio; Dario Sisto; Giovanni Alessio; Franco Dammacco
Journal:  Int Ophthalmol       Date:  2020-08-01       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.